Eisai is a major Japanese pharmaceutical company working to eliminate lymphatic filariasis (elephantiasis), one of the neglected tropical diseases (NTDs). In November 2011 it reached an agreement with the WHO to supply, free of charge, the treatment DEC (diethylcarbamazine) tablets to countries that need them for elimination. Exceeding its original 2.2 billion-tablet pledge, as of March 2025 it had delivered over 2.5 billion tablets to 32 countries, of which 8—Egypt, Sri Lanka, Thailand, the Maldives, Laos, Timor-Leste, Kiribati and Brazil—have achieved elimination of lymphatic filariasis. It has committed to continue free supply until elimination is achieved.
B
NARRATIVE VALUE
Certainty
●●● high
●●● high
ABCDEFG
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3BHistory grows each quarter
Eisai: Over 2.5 billion tablets of a neglected-tropical-disease drug, donated free. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
People in developing countries suffering lymphatic filariasis (elephantiasis) whom the drug never reached. By Eisai partnering with the WHO to supply DEC free, mass drug administration becomes possible and elimination advances. The benefit appears as a collective: as of March 2025 it had delivered over 2.5 billion tablets to 32 countries, with 8 achieving elimination.
Source nature: Eisai / WHO / P1 First-party / independent (WHO). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- Exceeding its 2011 WHO pledge (originally 2.2 billion tablets), it has committed to continue free DEC supply until elimination.P1 First-party / independent / Eisai / Global Health Progress
− effects (confirmed)
- No confirmed −.
Watching (unconfirmed; not counted in the assessment)
- A listed, for-profit pharmaceutical company (main business is selling medicines in developed markets)
- general industry debates, such as the efficacy and pricing of its Alzheimer's drugs (Leqembi, etc.).
Looking ahead (not included in the assessment)
- Continuing free supply until full elimination of lymphatic filariasis; expanding to other NTDs; verifying elimination outcomes; transparency on the pricing/efficacy of its core (developed-market) medicines.
A second look
The plus is free supply of treatment, and the resulting elimination, for people in developing countries suffering a neglected tropical disease (People), backed by the verifiable record of the WHO agreement, 2.5 billion-plus tablets, 32 countries and 8 eliminations. But Eisai is a listed, for-profit pharmaceutical company whose main business is selling medicines in developed markets, with the usual industry debates, such as the efficacy and pricing of its Alzheimer's drugs (Leqembi, etc.). Weighing the genuine, verified NTD-elimination plus, B/high.
Sources
+N1Eisai / WHO｜Initiatives for Lymphatic Filariasis｜2025｜🔗
+ effectEisai / Global Health Progress｜Supply of DEC for Lymphatic Filariasis Elimination｜2025｜🔗
How to read this assessment
A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top